Email Updates

You are here

Home

4 MARCH 2022 VOLUME 24 ISSUE 9

Media Coverage

  • Choosing an HIV Prevention Method

    A new HIV prevention study has found that when young women have access to and experience with two biomedical prevention options, the Dapivirine Vaginal Ring (DVR) and Truvada, an oral pre-exposure prophylaxis (PrEP) drug, almost all of them choose to continue using one of them.

    March 3, 2022
    PrEP
    Independent

  • Impact of PEPFAR on HIV Testing and ART Initiation

    HIV testing has decreased in 41 countries since 2018 but there has been a stable percent positivity, according to a presentation at the CROI 2022 virtual conference. The presentation also outlined that there has been an increase in newly-diagnosed persons who initiated antiretroviral therapy (ART), jumping from 60 to 90 percent.

    March 3, 2022
    Treatment
    Contagion Live

  • South Africa Ramps Up HIV Care Disrupted During COVID

    South Africa has the world’s highest number of HIV patients, but the COVID pandemic disrupted access to care, prevention, and testing, raising concerns of a spike in infections. With COVID numbers reducing, South Africa’s health experts are scrambling to step up HIV programs, as Linda Givetash reports from Johannesburg.

    March 3, 2022
    VOA News

  • Programme Offering HIV-Prevention Pills at Schools Proves To Be an ‘Amazing Success’

    Even though the rate of new HIV infections in young women and adolescent girls remains stubbornly high, provision and uptake of pills that can prevent HIV infection have generally been slow and lagging. One potential solution presented at the recent Conference on Retroviruses and Opportunistic Infections is to provide the pills at schools.

    March 3, 2022
    PrEP
    Daily Maverick

  • Low Knowledge of HIV PrEP Among Injection Drug Users

    HIV infects and destroys the immune system after being spread through contact with HIV-infected bodily fluids. In the United States, it most commonly spreads by anal or vaginal sex or by sharing drug injection equipment. When thinking about ways to reduce the risk of HIV infection, what often comes to mind is to engage in safe sex practices and never share drug injection equipment.1 However, many patients aren’t aware of another prevention option: pre-exposure prophylaxis (PrEP).

    March 2, 2022
    PrEP
    Pharmacy Times

  • Prioritise HIV Prevention Injection, Activists Say

    Rolling out a new HIV prevention injection should be a priority in South Africa, says Thandi Maluka, Executive Director of HIV activist group Positive Women’s Network (PWN). She says an HIV prevention injection, administered every two months, is going to make life easier for many people, especially young people. This is because the injection can be taken more discreetly than prevention pills.

    March 1, 2022
    PrEP
    Spotlight

  • South Africa Must Prioritise the HIV-Prevention Injection, Say Activists

    An HIV-prevention injection taken every two months was recently approved in the US. Several HIV activists interviewed say that access to the injection should be prioritised in South Africa and that we need to do a better job in rolling out the injection than we did with the roll-out of prevention pills.

    March 1, 2022
    PrEP
    Daily Maverick

  • HIV/AIDS Activists Worldwide Remember Treatment Pioneer Paul Farmer, MD

    Farmer died in his sleep at age 62 of a heart attack in Rwanda, on the grounds of a hospital and university he helped found. News of his early death instantly produced an outcry of grief worldwide from activists and officials in HIV, public health, human rights, and humanitarian aid.

    March 1, 2022
    Treatment
    The Body

  • Long-Acting Prevention and Treatment of HIV: CROI 2022 Update

    A MedPage Today video looks at long-acting prevention and treatment news from CROI with a discussion among Monica Gandhi, Carlos del Rio and Renee Heffron.

    February 28, 2022
    PrEP
    Medpage Today

  • Despite the Sensational Media Headlines, There Is Still No Viable Cure for HIV

    The US Food and Drug Administration issued a Complete Response Letter (CRL) to Gilead Sciences rejecting its New Drug Application (NDA) for lenacapavir… The rejection doesn’t appear to be over the drug’s efficacy. Instead, the agency cited Chemistry Manufacturing and Controls (CMC) problems associated with the compatibility of the drug with the proposed container vial.

    February 28, 2022
    Cure
    The Body

  • Transgender Texas Kids Are Terrified After Governor Orders That Parents Be Investigated for Child Abuse

    Some experts doubt that classifying gender-affirming care as child abuse would hold up in court, but families still feel targeted by Gov. Greg Abbott’s new order

    February 28, 2022
    Texas Tribune

  • Many Americans Still Paying High Costs Months After Insurers Were Ordered To Cover HIV Preventive Care

    Anthony Cantu, 31, counsels patients at a San Antonio health clinic about a daily pill shown to prevent HIV infection. Last summer, he started taking the medication himself, an approach called preexposure prophylaxis, better known as PrEP. The regimen requires laboratory tests every three months to ensure the powerful drug does not harm his kidneys and that he remains HIV-free.

    February 28, 2022
    PrEP
    CNN

  • Young Women Prefer Vaginal Ring to Daily Oral Pill for HIV Prevention

    Given the choice between a monthly vaginal ring and daily oral pre-exposure prophylaxis (PrEP) a course of HIV drugs taken by HIV-negative people to protect them against HIV infection, young African women overwhelmingly chose the [dapivirine] ring.

    February 26, 2022
    PrEP
    The East African

Published Research

Announcements